Cryptococcosis pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(23 intermediate revisions by 7 users not shown)
Line 5: Line 5:


==Overview==
==Overview==
[[Infection|Infective]] [[Cryptococcal infection|cryptococcal]] [[species]] are ubiquitous and natural exposure by [[inhalation]] is very common. [[Cryptococci]] are [[intracellular]] [[pathogens]]. Once they are [[Phagocytosis|phagocytosed]], they [[Germination|germinate]] and multiply within the [[macrophages]]. The [[immune response]] to [[cryptococcal infection]] is highly dependent on host [[T-cell]] function, [[interferon-γ]] and [[Tumor necrosis factor-alpha|TNF-α]] [[Cell signaling|signaling]]. Microscopically, ''[[Cryptococcus neoformans|Cryptococci]]'' are characterized by a thick [[mucopolysaccharide]] [[capsule]] with a refractile center.


==Pathophysiology==
==Pathophysiology==


=== Transmission ===
*[[Infection|Infective]] [[Cryptococcal infection|cryptococcal]] [[species]] are ubiquitous and natural exposure is very common.<ref name="pmid15788512">{{cite journal |vauthors=Wang CY, Wu HD, Hsueh PR |title=Nosocomial transmission of cryptococcosis |journal=N. Engl. J. Med. |volume=352 |issue=12 |pages=1271–2 |year=2005 |pmid=15788512 |doi=10.1056/NEJM200503243521225 |url=}}</ref>
*[[Infection]] occurs by [[inhalation]] of [[Aerosol|aerosolized]], dessicated [[basidiospores]].<ref name="pmid18365996">{{cite journal |vauthors=Jarvis JN, Harrison TS |title=Pulmonary cryptococcosis |journal=Semin Respir Crit Care Med |volume=29 |issue=2 |pages=141–50 |year=2008 |pmid=18365996 |doi=10.1055/s-2008-1063853 |url=}}</ref>


===Microscopic Pathology===
=== Virulence factors ===
* Cryptococcus [[polysaccharide]] capsule, [[phospholipase]] activity and [[extracellular]] vesicles play key roles in the survival of the organism within the host.<ref name="pmid25256589">{{cite journal |vauthors=Alspaugh JA |title=Virulence mechanisms and Cryptococcus neoformans pathogenesis |journal=Fungal Genet. Biol. |volume=78 |issue= |pages=55–8 |year=2015 |pmid=25256589 |pmc=4370805 |doi=10.1016/j.fgb.2014.09.004 |url=}}</ref>


====Cerebrum: Cryptococcosis (PAS stain)====
=== Pathogenesis ===
*Once these spores reach the [[alveoli]], they are [[phagocytosed]] by the [[Macrophages|alveolar macrophages]] without prior [[opsonization]] (usually required for [[yeast]] forms).
*''[[Cryptococcus|Cryptococci]]'' are [[intracellular]] [[pathogens]]. Once they are [[Phagocytosis|phagocytosed]], they [[Germination|germinate]] and multiply within the [[macrophages]].<ref name="pmid7927751">{{cite journal |vauthors=Goldman D, Lee SC, Casadevall A |title=Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat |journal=Infect. Immun. |volume=62 |issue=11 |pages=4755–61 |year=1994 |pmid=7927751 |pmc=303183 |doi= |url=}}</ref>
*Activated [[Macrophage|macrophages]] are capable of destroying the [[yeast]] forms that develop; however, non-activated macrophages act as [[Germination|germination centers]] for [[cryptococci]].<ref name="pmid24660045">{{cite journal |vauthors=Mansour MK, Reedy JL, Tam JM, Vyas JM |title=Macrophage Cryptococcus interactions: an update |journal=Curr Fungal Infect Rep |volume=8 |issue=1 |pages=109–115 |year=2014 |pmid=24660045 |pmc=3958962 |doi=10.1007/s12281-013-0165-7 |url=}}</ref>
*''[[Cryptococcus|Cryptococci]]'' have the ability to form giant cells that resist [[phagocytosis]] and have been hypothesized to play a role in latent [[Infection|infections]], and reactivation.<ref name="pmid24660045" />
*''[[Cryptococcus|Cryptococci]]'' also have the ability to change the number of sets of [[chromosomes]] they have during [[infection]]; this has been associated with heteroresistance to certain [[antifungal]] agents.<ref name="pmid23836187">{{cite journal |vauthors=Sionov E, Chang YC, Kwon-Chung KJ |title=Azole heteroresistance in Cryptococcus neoformans: emergence of resistant clones with chromosomal disomy in the mouse brain during fluconazole treatment |journal=Antimicrob. Agents Chemother. |volume=57 |issue=10 |pages=5127–30 |year=2013 |pmid=23836187 |pmc=3811407 |doi=10.1128/AAC.00694-13 |url=}}</ref>


=== Host response ===
*After exposure to desiccated [[yeast]] cells or [[Spore|spores]], patients may clear the [[infection]], contain it within [[Granuloma|granulomata]] as a latent [[infection]], or the infection may [[Disseminated disease|disseminate]]. This depends on the host's [[immune]] status or other, less well-understood mechanisms.
=== Dissemination ===
*[[Disseminated disease]] occurs among patients with compromised [[cell-mediated immunity]].
*The [[immune response]] to [[cryptococcal infection]] is highly dependent on host [[T-cell]] function, [[interferon-γ]] and [[Tumor necrosis factor-alpha|TNF-α]] [[Cell signaling|signaling]].
*[[Granuloma]] formation can be seen and may also be responsible for reactivation in patients presenting with [[Immunocompromised host|immunocompromised states]].<ref name="pmid22167400">{{cite journal| author=Brizendine KD, Baddley JW, Pappas PG| title=Pulmonary cryptococcosis. | journal=Semin Respir Crit Care Med | year= 2011 | volume= 32 | issue= 6 | pages= 727-34 | pmid=22167400 | doi=10.1055/s-0031-1295720 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22167400  }} </ref><ref name="pmid26685750">{{cite journal| author=May RC, Stone NR, Wiesner DL, Bicanic T, Nielsen K| title=Cryptococcus: from environmental saprophyte to global pathogen. | journal=Nat Rev Microbiol | year= 2015 | volume=  | issue=  | pages=  | pmid=26685750 | doi=10.1038/nrmicro.2015.6 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26685750  }} </ref>
==Microscopic Pathology==
[[File:Cryptococcosis of lung in patient with AIDS Mucicarmine stain.jpg|left|thumb|200px|Cryptococcosis of the lung in patient with [[AIDS]] (Mucicarmine stain), source: wikipedia.org]]
[[File:Cryptococcus_neoformans2.jpg|none|thumb|200px|Cryptococcosis in the [[cerebrospinal fluid]] with light India ink staining, source: wikipedia.org]]
<br>
*[[Cryptococcus]] exists in [[yeast]] form.
*It is round/ovoid and approximately 5-15 μm (resembles ''[[Histoplasma capsulatum|Histoplasma]]'' or ''[[Candida]]'', but often larger).
*It is characterized by a thick [[mucopolysaccharide]] [[Capsule (anatomy)|capsule]] with a refractile center.
*India ink staining is used for easy visualization of the capsule in [[cerebrospinal fluid]].<ref name="pmid8862601">{{cite journal| author=Zerpa R, Huicho L, Guillén A| title=Modified India ink preparation for Cryptococcus neoformans in cerebrospinal fluid specimens. | journal=J Clin Microbiol | year= 1996 | volume= 34 | issue= 9 | pages= 2290-1 | pmid=8862601 | doi= | pmc=PMC229234 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8862601  }} </ref>
*It has a tear drop-shaped [[budding]] pattern which is useful for differentiating ''[[Cryptococcus]]'' from ''[[Blastomyces]]'' and ''[[Histoplasma capsulatum|Histoplasma]]''.
*[[Cryptococcus|Cryptococcal infections]] are usually accompanied by very little [[inflammation]].
*[[Cryptococcus]] stain positive with [[methenamine]] [[Silver stain|silver]], [[Alcian blue]], and [[Periodic acid-Schiff stain|PAS]] (may be confused with corpora amylacea in the [[CNS]]).<ref name="librepath">Fungi. Libre Pathology (2015). http://librepathology.org/wiki/index.php/Fungi#Cryptococcosis. Accessed on December 31, 2015.</ref>
====Cryptococcosis (PAS stain)====
{{#ev:youtube|ZG0AcmtBLe4}}
{{#ev:youtube|ZG0AcmtBLe4}}


Line 18: Line 50:
{{Reflist|2}}
{{Reflist|2}}


[[Category:Needs content]]
[[Category:Fungal diseases]]
[[Category:Fungal diseases]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Emergency medicine]]
[[Category:Up-To-Date]]
[[Category:Infectious disease]]
[[Category:Pulmonology]]
[[Category:Neurology]]
[[Category:Dermatology]]

Latest revision as of 21:10, 29 July 2020

Cryptococcosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cryptococcosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cryptococcosis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cryptococcosis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cryptococcosis pathophysiology

CDC on Cryptococcosis pathophysiology

Cryptococcosis pathophysiology in the news

Blogs on Cryptococcosis pathophysiology

Directions to Hospitals Treating Cryptococcosis

Risk calculators and risk factors for Cryptococcosis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Serge Korjian M.D.; Yazan Daaboul, M.D.

Overview

Infective cryptococcal species are ubiquitous and natural exposure by inhalation is very common. Cryptococci are intracellular pathogens. Once they are phagocytosed, they germinate and multiply within the macrophages. The immune response to cryptococcal infection is highly dependent on host T-cell function, interferon-γ and TNF-α signaling. Microscopically, Cryptococci are characterized by a thick mucopolysaccharide capsule with a refractile center.

Pathophysiology

Transmission

Virulence factors

Pathogenesis

Host response

Dissemination

Microscopic Pathology

Cryptococcosis of the lung in patient with AIDS (Mucicarmine stain), source: wikipedia.org
Cryptococcosis in the cerebrospinal fluid with light India ink staining, source: wikipedia.org



Cryptococcosis (PAS stain)

{{#ev:youtube|ZG0AcmtBLe4}}

References

  1. Wang CY, Wu HD, Hsueh PR (2005). "Nosocomial transmission of cryptococcosis". N. Engl. J. Med. 352 (12): 1271–2. doi:10.1056/NEJM200503243521225. PMID 15788512.
  2. Jarvis JN, Harrison TS (2008). "Pulmonary cryptococcosis". Semin Respir Crit Care Med. 29 (2): 141–50. doi:10.1055/s-2008-1063853. PMID 18365996.
  3. Alspaugh JA (2015). "Virulence mechanisms and Cryptococcus neoformans pathogenesis". Fungal Genet. Biol. 78: 55–8. doi:10.1016/j.fgb.2014.09.004. PMC 4370805. PMID 25256589.
  4. Goldman D, Lee SC, Casadevall A (1994). "Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat". Infect. Immun. 62 (11): 4755–61. PMC 303183. PMID 7927751.
  5. 5.0 5.1 Mansour MK, Reedy JL, Tam JM, Vyas JM (2014). "Macrophage Cryptococcus interactions: an update". Curr Fungal Infect Rep. 8 (1): 109–115. doi:10.1007/s12281-013-0165-7. PMC 3958962. PMID 24660045.
  6. Sionov E, Chang YC, Kwon-Chung KJ (2013). "Azole heteroresistance in Cryptococcus neoformans: emergence of resistant clones with chromosomal disomy in the mouse brain during fluconazole treatment". Antimicrob. Agents Chemother. 57 (10): 5127–30. doi:10.1128/AAC.00694-13. PMC 3811407. PMID 23836187.
  7. Brizendine KD, Baddley JW, Pappas PG (2011). "Pulmonary cryptococcosis". Semin Respir Crit Care Med. 32 (6): 727–34. doi:10.1055/s-0031-1295720. PMID 22167400.
  8. May RC, Stone NR, Wiesner DL, Bicanic T, Nielsen K (2015). "Cryptococcus: from environmental saprophyte to global pathogen". Nat Rev Microbiol. doi:10.1038/nrmicro.2015.6. PMID 26685750.
  9. Zerpa R, Huicho L, Guillén A (1996). "Modified India ink preparation for Cryptococcus neoformans in cerebrospinal fluid specimens". J Clin Microbiol. 34 (9): 2290–1. PMC 229234. PMID 8862601.
  10. Fungi. Libre Pathology (2015). http://librepathology.org/wiki/index.php/Fungi#Cryptococcosis. Accessed on December 31, 2015.